EA201690936A1 - Применение цистеамина и его производных для лечения митохондриальных заболеваний - Google Patents

Применение цистеамина и его производных для лечения митохондриальных заболеваний

Info

Publication number
EA201690936A1
EA201690936A1 EA201690936A EA201690936A EA201690936A1 EA 201690936 A1 EA201690936 A1 EA 201690936A1 EA 201690936 A EA201690936 A EA 201690936A EA 201690936 A EA201690936 A EA 201690936A EA 201690936 A1 EA201690936 A1 EA 201690936A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
cystemin
treatment
application
mitochondrial diseases
Prior art date
Application number
EA201690936A
Other languages
English (en)
Inventor
Патрис Риу
Тодд К. Занкел
Original Assignee
Раптор Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Раптор Фармасьютикалз Инк. filed Critical Раптор Фармасьютикалз Инк.
Publication of EA201690936A1 publication Critical patent/EA201690936A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение направлено на способы лечения наследственного или приобретенного митохондриального заболевания с применением цистеаминового продукта, например цистеамина или цистамина, либо их производных.
EA201690936A 2013-11-06 2014-11-06 Применение цистеамина и его производных для лечения митохондриальных заболеваний EA201690936A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900772P 2013-11-06 2013-11-06
PCT/US2014/064336 WO2015069888A2 (en) 2013-11-06 2014-11-06 Use of cysteamine and derivatives thereof to treat mitochondrial diseases

Publications (1)

Publication Number Publication Date
EA201690936A1 true EA201690936A1 (ru) 2016-08-31

Family

ID=53007221

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690936A EA201690936A1 (ru) 2013-11-06 2014-11-06 Применение цистеамина и его производных для лечения митохондриальных заболеваний

Country Status (13)

Country Link
US (1) US20150125526A1 (ru)
EP (1) EP3065725A4 (ru)
JP (1) JP2016540827A (ru)
KR (1) KR20160070154A (ru)
CN (1) CN105873579A (ru)
CA (1) CA2928442A1 (ru)
CL (1) CL2016001098A1 (ru)
EA (1) EA201690936A1 (ru)
IL (1) IL245231A0 (ru)
MX (1) MX2016005858A (ru)
PH (1) PH12016500842A1 (ru)
TW (1) TW201605434A (ru)
WO (1) WO2015069888A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991099A1 (en) * 2015-07-02 2017-01-05 Horizon Orphan Llc Ado-resistant cysteamine analogs and uses thereof
AU2016369616B2 (en) 2015-12-17 2021-03-25 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2018013811A1 (en) * 2016-07-14 2018-01-18 The Regents Of The University Of California Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders
CN109996886A (zh) * 2016-11-02 2019-07-09 国立大学法人京都大学 Pd-1信号抑制剂疾病治疗中有效性判定标记
JP7427308B2 (ja) 2021-05-24 2024-02-05 国立大学法人岩手大学 網膜の神経細胞の保護剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1299545A2 (en) * 2000-07-07 2003-04-09 Incyte Genomics, Inc. Drug metabolizing enzymes
US20110301235A1 (en) * 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
US20120309785A1 (en) * 2010-12-03 2012-12-06 Bill Piu Chan Use of Cysteamine in Treating Parkinson's Disease

Also Published As

Publication number Publication date
PH12016500842A1 (en) 2016-07-04
CN105873579A (zh) 2016-08-17
TW201605434A (zh) 2016-02-16
EP3065725A4 (en) 2017-06-14
WO2015069888A3 (en) 2015-11-12
MX2016005858A (es) 2016-08-11
CL2016001098A1 (es) 2016-12-23
CA2928442A1 (en) 2015-05-14
IL245231A0 (en) 2016-06-30
US20150125526A1 (en) 2015-05-07
JP2016540827A (ja) 2016-12-28
WO2015069888A2 (en) 2015-05-14
EP3065725A2 (en) 2016-09-14
KR20160070154A (ko) 2016-06-17

Similar Documents

Publication Publication Date Title
CO2017011484A2 (es) Inhibidores de bromodominio
EA201800367A1 (ru) Способы лечения болезни хантингтона
EA201691582A1 (ru) Новые фармацевтические препараты
EA201790273A1 (ru) Флагеллиновые композиции и их применение
CR20160229A (es) Inhibidires de bromodominio
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201691940A1 (ru) Новые соединения
EA201691354A1 (ru) Терапевтические ингибирующие соединения
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201491854A1 (ru) Асимметрический синтез соединений спирооксиндола, полезных в качестве терапевтических средств
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201690936A1 (ru) Применение цистеамина и его производных для лечения митохондриальных заболеваний
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
CO2017001087A2 (es) Anticuerpos anti proteína similar a angiopoyetina 4
EA201600288A1 (ru) Замещенные фенилаланиновые производные
UY35745A (es) Derivados sustituidos de fenilalanina
EA201792610A1 (ru) Способ лечения неврологического заболевания
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
EA201792085A1 (ru) Смешанные дисульфидные конъюгаты тиенопиридиновых соединений и их применение